The key results are:
i) Establishment of protocols and workflows for native MS and HDX-MS experiments. Native MS preserves non-covalent protein interactions in the gas phase, allowing the investigation of intact macromolecular assemblies in their folded states. These experiments provide insights into the composition, stoichiometry, and structural organisation of protein complexes, as well as their interactions with other biomolecules. In addition, we have established dedicated HDX-MS workflows for the analysis of soluble and membrane proteins. These methodologies enable the characterisation of conformational dynamics and structural changes, providing mechanistic insights into how proteins and complexes respond to ligand binding, and other regulatory events (ER-1,2,12)
ii) Development of lipidomics MS protocols
We have developed specialised workflows for (un)targeted lipidomics. These complementary approaches enable the comprehensive identification, quantification, and characterisation of diverse lipid species across a wide range of biological samples (ER-1,2,12)
iii)Protein expression & purification
We have established robust workflows for the recombinant expression and purification of proteins from bacterial and mammalian expression systems. These protocols have been optimised to produce high-quality protein samples suitable for MS analyses. These methodologies encompass construct design, expression optimisation, affinity and chromatographic purification strategies, and rigorous QC procedures to ensure protein purity, and stability. These capabilities provide a reliable platform for the production of soluble and membrane proteins, enabling the investigation of a broad range of biological and medical targets (ER-1,2,12)
iv) Initial results on soluble and membrane proteins
We have conducted structural MS investigations on a range of soluble proteins, including AL55, Tau, and SOD1, generating high-quality datasets that demonstrate the robustness and reproducibility of the established workflows. In parallel, we have evaluated the performance of the instrumentation for the analysis of membrane proteins using XylE transporter as model system (ER-1,2,12)
v) Exploration of commercialisation and intellectual property (IPR)
We have explored commercialisation pathways and IPs associated with the developed technologies. In particular, we participated in the BioStart scheme and engaged with the Technology Transfer Office at BSRC Fleming to evaluate potential spin-out routes and to assess market potential of the platform technologies. Such activities have helped define strategic directions for future development, including technology positioning, and routes towards academic and industrial impact (ER-3,11,12)